Iterative Scopes to Present Three Abstracts on Artificial Intelligence Applications for GI Endoscopy at DDW 2022

Two abstracts include data generated in collaboration with Eli Lilly and Company and focusing on an AI-driven automated disease scoring technology aimed to accelerate clinical trials for ulcerative colitis

A plenary session will feature the first publicly available data from the clinical registration study on SKOUT™, the company’s automated polyp detection algorithm in colonoscopy, representing results from the largest, US-based clinical trial evaluating AI in colorectal cancer screening conducted to date

Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, announced that its artificial intelligence platforms will be featured in three abstract presentations at the upcoming Digestive Disease Week 2022 (DDW 2022). The meeting will take place virtually and onsite at the San Diego Convention Center in San Diego, CA, from May 21 to May 24.

Latest Aithority Insights: AiM Future Joins the Edge AI and Vision Alliance

“Development of a novel ulcerative colitis (UC) endoscopic activity prediction model using machine learning (ML)”

Experts in inflammatory bowel disease (IBD) and artificial intelligence (AI) will present two abstracts discussing data on the company’s endoscopic scoring algorithms in ulcerative colitis (UC), a condition included in the umbrella of IBD, developed in collaboration with Eli Lilly and Company.

The data are drawn from an innovative partnership between Iterative Scopes and Lilly, focusing on studying the effectiveness of machine learning (ML) models to automatically score endoscopic disease severity in UC. Progress in IBD research is hindered by variability in the human interpretation of endoscopic severity. This unique ML approach incorporates novel methods of interpreting and integrating visual data into the assessment of clinical trial endoscopic endpoints. This data has the potential to be considered as a substitute to human central readers, which may reduce clinical trial costs and accelerate IBD research.

Browse The Complete News About Aithority : Cobalt Iron Earns Patent for Machine-Learning-Driven Authentication Control

Aasma Shaukat, MD, MPH, Robert M. and Mary H. Glickman Professor of Medicine and Gastroenterology at NYU Grossman School of Medicine, and a leader of the Iterative Scopes advisory board, will present the first publicly available registration trial data on SKOUT™, the company’s automated polyp detection algorithm for colorectal cancer screening, in a plenary session on “Late-Breaking Clinical Science Abstracts.” The plenary sessions at DDW are the forum for highlighting some of the year’s best research abstracts as determined by the conference organizers. In her discussion, Dr. Shaukat will highlight results of a multicentered, randomized clinical trial in the US assessing whether SKOUT is superior to standard colonoscopy in increasing the adenomas per colonoscopy.

SKOUT has a pending 510(k) and is not available for sale in the United States. SKOUT received its CE Mark certification in 2021.

“We founded Iterative Scopes four years ago to change the trajectory of GI drug development and clinical care, and we are extremely excited to share results of Iterative Scopes’ work in applying cutting edge, computational approaches towards achieving this goal,” said Jonathan Ng, MBBS, the founder and CEO of Iterative Scopes. “We are excited to share our work with the clinical community at DDW, through these presentations and the other events surrounding DDW.”

Read More About Aithority News : Gradiant Acquires Synauta, Machine Learning Company, to Advance AI Technology in Water

[To share your insights with us, please write to sghosh@martechseries.com]